These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Current status of medical treatment for inflammatory bowel disease. Goldstein F Am J Gastroenterol; 1983 Dec; 78(12):841-4. PubMed ID: 6139956 [No Abstract] [Full Text] [Related]
44. Therapy of inflammatory bowel disease, including use of immunosuppressive agents. Korelitz BI Clin Gastroenterol; 1980 May; 9(2):331-49. PubMed ID: 6104550 [No Abstract] [Full Text] [Related]
45. Management of varicella infection during the course of inflammatory bowel disease. Mouzas IA; Greenstein AJ; Giannadaki E; Balasubramanian S; Manousos ON; Sachar DB Am J Gastroenterol; 1997 Sep; 92(9):1534-7. PubMed ID: 9317080 [TBL] [Abstract][Full Text] [Related]
46. Medical treatment of ulcerative colitis and Crohn's disease. Rhodes JM J Clin Hosp Pharm; 1983 Sep; 8(3):219-32. PubMed ID: 6138368 [No Abstract] [Full Text] [Related]
47. [New salazosulfapyridine derivatives. Progress in the treatment of chronic inflammatory diseases of the intestines?]. Modigliani R; Rambaud JC Gastroenterol Clin Biol; 1987 Apr; 11(4):325-32. PubMed ID: 2884162 [No Abstract] [Full Text] [Related]
48. [Evaluation of the results of radical surgical treatment of Crohn disease as related to a diversified postoperative treatment]. Morettini A; Scartabelli S; Bechi P; Bartolozzi C; Taddei GL; Bartoletti L; D'Albasio G; Allamani A Recenti Prog Med; 1981 Jun; 70(6):669-73. PubMed ID: 6115459 [No Abstract] [Full Text] [Related]
49. [Local or systemic treatment of inflammatory bowel diseases?]. Schmassmann A; Halter F Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092 [TBL] [Abstract][Full Text] [Related]
50. An approach to the medical management of inflammatory bowel disease. Bartnik W; Shorter RG Mater Med Pol; 1981; 13(2):93-9. PubMed ID: 6124660 [No Abstract] [Full Text] [Related]
51. Pulmonary function in patients with inflammatory bowel disease. Eade OE; Smith CL; Alexander JR; Whorwell PJ Am J Gastroenterol; 1980 Feb; 73(2):154-6. PubMed ID: 6104919 [TBL] [Abstract][Full Text] [Related]
52. Will there be a next generation of sulfasalazine? Goldman P Gastroenterology; 1982 Nov; 83(5):1138-41. PubMed ID: 6126420 [No Abstract] [Full Text] [Related]
55. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. Mossop H; Davies P; Murphy MS J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861 [TBL] [Abstract][Full Text] [Related]
56. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Faintuch J; Mott CB; Machado MC Int Surg; 1985; 70(3):271-2. PubMed ID: 2872181 [TBL] [Abstract][Full Text] [Related]
57. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece. Christodoulou D; Katsanos K; Baltayannis G; Tzabouras N; Tsianos EV Hepatogastroenterology; 2003; 50(52):1021-4. PubMed ID: 12845970 [TBL] [Abstract][Full Text] [Related]
59. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Glas J; Török HP; Daczo J; Tonenchi L; Folwaczny M; Folwaczny C Eur J Med Res; 2005 Dec; 10(12):535-8. PubMed ID: 16356870 [TBL] [Abstract][Full Text] [Related]
60. [Current medical treatment of inflammatory bowel disease]. Bosques-Padilla F Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]